Featured ArticlesHome page featureThe Latest

Acne Vulgaris Treatment Falls Short

Featured Article

Featured Article

Acne Vulgaris Treatment Falls Short

The majority of acne patients are not likely to achieve success according to FDA guidance. Is the FDA guidance too rigorous?

More Acne News

Luciana Nofal

What is the likelihood of treatment success in patients with acne vulgaris?

According the FDA, success is defined as clear or almost clear.  The FDA recommends using the IGA grading scale. The different grades include clear (grade 0), almost clear (grade 1), mild severity (grade 2), moderate severity (grade 3), and severe (grade 4). However, there are many different scales for grading acne severity.

Data from the 2012 to 2016 NAMCS was used to determine the number of medications prescribed for outpatient visits when isotretinoin was prescribed or when isotretinoin was not prescribed and the one and only diagnosis was acne. These surveys were developed and implemented by the National Center of Health Statistics, part of the Center for Disease Control and Prevention (CDC). Results from the survey provide nationally representative yearly estimates of non-hospital-based outpatient healthcare utilization.

This study finds the majority of acne patients are not likely to achieve success according to FDA guidance. The study proposes that the FDA guidance may be too rigorous. An alternative hypothesis is that most acne patients are undertreated.

Further studies should be done to demonstrate a clinically meaningful severity difference, or minimum clinically important difference, in acne severity and these studies may help redefine acne treatment success.

How did the oral and topical medications perform? What drugs were the most efficacious at the end of 12 weeks?

The authors compared 19 oral and topical acne treatments and the results may be surprising. Read the article to find out.

  1. Adapalene and benzoyl peroxide gel 0.1%/2.5%
  2. Adapalene gel 0.1%
  3. Adapalene gel 0.3%
  4. Benzoyl Peroxide gel 2.5%
  5. Clindamycin gel 1.2%
  6. Clindamycin phosphate and benzoyl peroxide gel 1.2%/2.5%
  7. Clindamycin phosphate and tretinoin gel 1.2%/0.025%
  8. Dapsone gel 5%
  9. Dapsone gel 7.5%
  10. Minocycline foam 4%
  11. Tazarotene cream 0.1%
  12. Tazarotene foam 0.1%
  13. Tretinoin lotion 0.05%
  14. Trifarotene cream
  15. Doxycycline calcium tablet
  16. Drospirenone/ethinyl estradiol tablet
  17. Extended release minocycline
  18. Isotretinoin capsule
  19. Sarecycline tablet

 

Acne Vulgaris: The Majority of Patients Do Not Achieve Success According to FDA Guidance
Keshav Patel MS, Katherine Baquerizo Nole MD, Alan Fleischer Jr. MD

You May Also Like

Journal of Drugs in Dermatology JDD Article Current Use of Neoadjuvant Hedgehog Inhibitors Among Mohs Surgeons: Results of a Cross-Sectional Survey

Current Use of Neoadjuvant Hedgehog Inhibitors Among Mohs Surgeons: Results of a Cross-Sectional Survey

| Featured Articles, Latest News, Skin Cancer, The Latest | No Comments
Neoadjuvant Hedgehog Inhibitors: Gaining Ground in Mohs for BCC? A recent survey of American College of Mohs Surgery members reveals that 22% of Mohs surgeons are already using hedgehog pathway…

JDD in the News: Proposed Universal Classification System for Topical Corticosteroids 

| Featured Articles, JDD Highlights, JDD in the Media, Skincare, The Latest | No Comments
Healio profiled a new universal classification system for topical corticosteroids that could reduce confusion across countries. The system was published in the May Journal of Drugs in Dermatology in an…

A Scientific Approach to Defining, Evaluating, and Treating Pre-Aging With a Cosmetic Regimen Containing a Novel Cosmetic Peptide, Acetyl Dipeptide-31 Amide (AP31)

| Featured Articles, The Latest, Video Abstract | No Comments
Featured Video Abstract Check out our all new video abstract from Cheri Frey, MD, where she discusses a scientific approach to defining, evaluating, and treating pre-aging with a cosmetic regimen…

Leave a Reply